EP300 and urinary bladder carcinoma: found that EP300 loss-of-function relieved p300’s transcriptional and/or physical-tethering inhibition on IL-1α signaling, subsequently activating the IL-6/JAK/STAT3 pathway to drive oncogenesis in bladder cancer (47).